Basilea Pharmaceutica company profile

BSLN · SIX · CHF

Compare Basilea Pharmaceutica
CHF 72.80Change from previous close: +0.14%Absolute change: +CHF 0.10

Close · November 20, 2026

Company profile

Basilea Pharmaceutica has 200 employees and is headquartered in Allschwil, Switzerland.

Anti-infective medicines are the core of Basilea Pharmaceutica AG's business, which develops and sells treatments for serious bacterial and fungal infections. Its marketed products are Cresemba, an antifungal given intravenously or orally, and Zevtera, a ceftobiprole-based antibiotic used for pneumonia, Staphylococcus aureus bacteremia and skin infections. The pipeline includes fosmanogepix, a broad-spectrum antifungal for mold infections, and ceftibuten-ledaborbactam etzadroxil, an oral antibiotic for complicated urinary tract infections. The company also works with Prokaryotics, Inc on antifungals against drug-resistant pathogens and with Phare Bio on generative AI for antibiotic discovery.

In the fiscal year ended December 2025, revenue reached CHF 232.4 million, up 11.4% from the previous year, and net income was CHF 40.2 million. The company, founded in 2000, is headquartered in Allschwil, Switzerland, and employs 200 people.

Company facts

Industry
Biotechnology
Headquarters
Hegenheimermattweg 167b, 4123, Allschwil
Employees
200
Chief executive
David Veitch
Founded
2000
Fiscal year
January - December
Listing
BSLN · SIX
Currency
CHF
ISIN
CH0011432447

Basilea Pharmaceutica and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Basilea PharmaceuticaBSLNSwitzerland$1.07B20024.2%18.1
Pharma MarPHMSpain$1.1B50521.3%14.7
IdorsiaIDIASwitzerland$1.26B424-68.4%—
PhilogenPHILItaly$905.96M23079.1%3.67
InventivaIVAFrance$890.8M87-5,980.9%—
Pharming GroupPHARMNetherlands$841.25M40712.8%36.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Basilea Pharmaceutica with its competitors